Therapy in the Early Stage: Incretins

May 2011
Diabetes Care;May2011 Supplement 2, Vol. 34, pS264
Academic Journal
The article examines the use of incretin-based therapies in the early stage of type 2 diabetes. Incretin mimetics receptor agonists and incretin enhancers are the two types of incretin-based therapies. A member of the glucagon superfamily, incretin is a gut-derived hormone released in response to nutrient ingestion, which are mainly glucose and fat. The effects of incretins or incretin-based therapies on various organs, including pancreas, gastrointestinal system, central and peripheral nervous system and insulin-sensitive tissues, are described.


Related Articles

  • Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Ahrén, Bo // Nature Reviews Drug Discovery;May2009, Vol. 8 Issue 5, p369 

    Islet dysfunction — characterized by a combination of defective insulin secretion, inappropriately high glucagon secretion and reduced β-cell mass — has a central role in the pathophysiology of type 2 diabetes. Several G protein-coupled receptors (GPCRs) expressed in islet...

  • GLP-1: target for a new class of antidiabetic agents? Edwards, Mark B.; Edwards, C Mark B // Journal of the Royal Society of Medicine;Jun2004, Vol. 97 Issue 6, p270 

    The article provides information on glucagon-like peptide-1 (GLP-1) hormone. GLP-1 and glucose-dependent insulinotropic peptide are responsible for the differences between 2 values known as the incretin effect. This GLP-1 decreases the glucose levels of type 2 diabetic patient and stimulates...

  • Physiological Interactions of Pancreatic Hormones and Incretins in Type 2 Diabetes Mellitus. Méndez, José D.; González, Claudia P.; Ledezma, Isis G.; y Gonzáles Rubio, Manuel García Luna; Valenzuela, Verna Méndez // Advances in Environmental Biology;Jan-Apr2009, Vol. 3 Issue 1, p53 

    It is known that after meal ingestion two incretins on its active form; glucose-dependent insulinotropic polypeptide (GIP [1-42]) and glucagon like peptide -1 (GLP-1 [7-36]) are released from duodenal K-cells and ileum-colon L-cells, respectively. GIP and GLP-1 induce insulin release from...

  • The GLP-1 Derivative NN2211 Restores β-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose. Chang, Annette M.; Jakobsen, Grethe; Sturis, Jeppe; Smith, Marla J.; Bloem, Cathie J.; An, Bob; Galecki, Andrzej; Halter, Jeffrey B. // Diabetes;Jul2003, Vol. 52 Issue 7, p1786 

    Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion in a glucose-dependent manner, but its short half-life limits its therapeutic potential. We tested NN2211, a long-acting GLP-1 derivative, in 10 subjects with type 2 diabetes (means ± SD: age 63 ± 8 years, BMI 30.1 ± 4.2...

  • Cytotoxic Effects of Human Islet Amyloid Polypeptide on Primary Islet α-Cells and β-Cells: Implications for Understanding the Pathogenesis of Type 2 Diabetes. Cheng, Florence; Marzban, Lucy // Diabetes;Jun2007 Supplement 1, Vol. 56, pA410 

    Progressive loss of islet β-cell mass and function along with elevated plasma glucagon levels are key defects in type 2 diabetes (T2D) that lead to hyperglycemia. Islet amyloid - formed by aggregation of the β-cell peptide islet amyloid polypeptide (LAPP) - is a pathologic characteristic...

  • Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. Shyangdan, Deepson S.; Royle, Pamela L.; Clar, Christine; Sharma, Pawana; Waugh, Norman R. // BMC Endocrine Disorders;2010, Vol. 10, p20 

    Background: Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis, suppressing glucagon secretion, and delaying...

  • Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study. Ulhôa Tostes, Glauce Cordeiro; Rosário Cunha, Maria; Rosa Tsumeshiro Fukui; Silva Correia, Márcia Regina; Rocha, Dalva Marreiro; dos Santos, Rosa Ferreira; da Silva, Maria Elizabeth Rossi // Diabetology & Metabolic Syndrome;1/4/2016, Vol. 4, p1 

    Background: To compare the effects of nateglinide and rosiglitazone on inflammatory markers, GLP-1 levels and metabolic profile in patients with type 2 diabetes (DM2). Methods: A prospective study was performed in 20 patients with DM2, mean age 51.82 ± 8.05 years, previously treated with...

  • Loss of β-Cell Identity Occurs in Type 2 Diabetes and Is Associated With Islet Amyloid Deposits. Spijker, H. Siebe; Song, Heein; Ellenbroek, Johanne H.; Roefs, Maaike M.; Engelse, Marten A.; Bos, Erik; Koster, Abraham J.; Rabelink, Ton J.; Hansen, Barbara C.; Clark, Anne; Carlotti, Françoise; de Koning, Eelco J. P. // Diabetes;Aug2015, Vol. 64 Issue 8, p2828 

    Loss of pancreatic islet β-cell mass and β-cell dysfunction are central in the development of type 2 diabetes (T2DM). We recently showed that mature human insulin-containing β-cells can convert into glucagon-containing α-cells ex vivo. This loss of β-cell identity was...

  • The Incretin Approach for Diabetes Treatment. Holst, Jens Juul; Ørskov, Cathrine // Diabetes;Dec2004 Supplement, Vol. 53, pS197 

    Glucagon-like peptide (GLP)-1 is a gut hormone that stimulates insulin secretion, gene expression, and β-cell growth. Together with the related hormone glucose-dependent insulinotropic polypeptide (GIP), it is responsible for the incretin effect, the augmentation of insulin secretion after...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics